COMPENDIUM
Systematic analysis of clinical-stage biotechnology assets.
Latest Published Research
View Full Archive →ARQT Restrospective: The Anatomy of a Commercial Biotech Triumph
A comprehensive, highly granular historical reconstruction of Arcutis Biotherapeutics. Charting the transition from a 2016 startup to a cash-flow-positive commercial powerhouse via the execution of the ZORYVE (roflumilast) franchise.
$ARQT
Ionizing Alpha: The Case for Targeted Radiopharmaceuticals
An analysis of the 'Search & Destroy' paradigm shift in oncology. Evaluating the therapeutic moat of Alpha-emitters, isotope supply chain logistics, and the M&A land-grab by Big Pharma.
$RADX$ATNM$CU6$LNTH
The Immune Convergence: Linking VIR and BBOT via the Immunotherapy Axis
An analysis of the structural overlap between infectious disease and oncology. Exploring Vir Biotechnology’s T-cell engagers (TCE) and BridgeBio Oncology’s (BBOT) RAS-pathway precision, through the lens of 'Harnessing the Host' to solve chronic pathology.
$VIR$BBOT